Daniel Bednarik Ph.D.
About Daniel Bednarik Ph.D.
Daniel Bednarik, Ph.D., is the Senior Vice President of Molecular Engineering & Protein Design with over 30 years of experience in translational science and executive leadership in biotechnology.
Title: Senior Vice President, Molecular Engineering & Protein Design
Daniel Bednarik, Ph.D., holds the position of Senior Vice President at a leading molecular engineering and protein design firm. In this role, he oversees advanced research and development initiatives, focusing on innovative solutions in molecular engineering and protein design. His extensive experience and leadership play a crucial role in driving the company's technological advancements.
Over 30 Years of Experience in Translational Science and Executive Leadership
With over three decades of experience, Daniel Bednarik, Ph.D., is a seasoned translational scientist and executive. His career has been dedicated to transforming promising technologies into viable products, particularly in the realms of cancer and cardiovascular disease. His expertise encompasses both scientific research and strategic management, making significant contributions to the companies he has served.
Previous Experience at Intrexon Corp and Other Leading Companies
Daniel Bednarik, Ph.D., previously served as the Vice President of the Molecular Engineering Unit at Intrexon Corp. His career also includes senior roles at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. His work in these positions involved spearheading significant projects in translational medicine, contributing to advancements in therapeutic areas such as cancer and cardiovascular diseases.
Significant Contributions to Translational Medicine Projects
Daniel Bednarik, Ph.D., has led various innovative projects in translational medicine, addressing therapeutic areas like cancer and cardiovascular diseases. At Gene Logic, Inc., he was instrumental in creating the largest known cardiovascular transcriptomic gene expression database. His leadership in these projects has advanced the understanding and treatment of these critical health issues.
Recipient of DARPA Contract and Post-Doctoral Fellowship at Johns Hopkins
In 2006, Daniel Bednarik, Ph.D., was awarded a $1.7M contract from the Defense Advanced Research Projects Agency (DARPA) to develop a novel non-host method for rapid vaccine manufacture. Following the completion of his doctoral studies, he completed a post-doctoral fellowship at the Johns Hopkins University Oncology Center, further honing his expertise in oncology and translational medicine.